Plain-English translation of NCT07011745 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer's Disease research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether a new medication called KarXT + KarX-EC can help reduce agitation and aggression in people who have Alzheimer's disease. About half of participants will receive the medication, and half will receive a placebo (inactive pill) so researchers can fairly compare how well the treatment works. The study will measure whether this medication is safe and effective at calming agitation related to Alzheimer's.
Agitation and aggression are common and distressing symptoms in people with Alzheimer's disease, but current treatment options are limited and don't work well for everyone. This trial is testing whether the medication could offer a safer and more effective option for managing these difficult symptoms.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will visit the research site multiple times over the course of the study. At each visit, a doctor or nurse will assess your symptoms, ask about your well-being, and check for any side effects. Your caregiver will attend visits with you and help track how you're doing between appointments. You will take either the new medication or a placebo by mouth—you won't know which one you're receiving. The study team will use standard questionnaires and rating scales to measure whether your agitation improves and whether the treatment is safe.
AI-generated summary from trial data · Jun 28, 2026 · Not medical advice
United States